Experienced in Epidermolytic Hyperkeratosis

Hagen R. Ott

Janusz Korczak Allee 12, 
Hannover, NI, DE 
Experienced in Epidermolytic Hyperkeratosis
Janusz Korczak Allee 12, 
Hannover, NI, DE 
OverviewLocationsClinical Research

Overview

Hagen Ott practices in Hannover, Germany. Mr. Ott is rated as an Experienced expert by MediFind in the treatment of Epidermolytic Hyperkeratosis. His top areas of expertise are Nonbullous Congenital Ichthyosiform Erythroderma, Netherton Syndrome, Epidermolysis Bullosa, and Atopic Dermatitis.

His clinical research consists of co-authoring 120 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Epidermolytic Hyperkeratosis.

Gender
Male

Locations

Janusz Korczak Allee 12, Hannover, NI 30173, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow-up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa
Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow-up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa
Enrollment Status: Completed
Publish Date: July 20, 2023
Intervention Type: Drug
Study Drug: Oleogel-S10
Study Phase: Phase 3
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
Enrollment Status: Completed
Publish Date: April 09, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

120 Total Publications

Family dermatology life quality index (F-DLQI): German validation and applicability to parents of infants and toddlers with dermatological conditions.
Family dermatology life quality index (F-DLQI): German validation and applicability to parents of infants and toddlers with dermatological conditions.
Journal: European journal of pediatrics
Published: June 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ott's expertise for a condition
ConditionClose
    View All 45 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile